Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


RATIONALE: Topotecan may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying how well topotecan works in treating patients with metastatic or unresectable solid tumors.

Study summary:

OBJECTIVES: Primary - Determine whether chronic administration of topotecan inhibits hypoxia inducible factor-1α (HIF-1α) in patients with metastatic or unresectable solid tumors expressing HIF-1α. Secondary - Determine tumor angiogenesis using dynamic contrast-enhanced MRI in patients treated with this drug. - Determine the pharmacokinetics of this drug in these patients. - Determine tumor response in patients treated with this drug. OUTLINE: This is a pilot study. Patients receive oral topotecan once daily on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients who are in remission are followed every 3 months until the start of salvage therapy. PROJECTED ACCRUAL: A total of 13-20 patients will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor - Metastatic or unresectable disease - Progressive disease after prior standard therapy OR no standard therapy exists - Hypoxia inducible factor-1α (HIF-1α)-expressing tumor by immunohistochemistry, defined as > 10% of cells staining positive for HIF-1α - Tumor accessible by biopsy with minimal or small amount of risk to the patient - No known brain metastases - Previously treated brain metastases that have remained stable for ≥ 4 months without steroids or antiseizure medication allowed at the discretion of the investigator PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - More than 3 months Hematopoietic - WBC ≥ 3,000/mm^3 - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 Hepatic - AST and ALT ≤ 2.5 times upper limit of normal (ULN) - Bilirubin ≤ 1.5 times ULN - PT and PTT ≤ 1.5 times ULN Renal - Creatinine ≤ 1.5 mg/dL OR - Creatinine clearance ≥ 50 mL/min Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No known HIV positivity - No known immune deficiency syndrome - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to topotecan or to any component of the topotecan formulation - No active peptic ulcer or gastrointestinal condition that could alter absorption or motility - No other unstable medical illness PRIOR CONCURRENT THERAPY: Biologic therapy - More than 4 weeks since prior anticancer vaccines Chemotherapy - More than 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas, mitomycin, or UCN-01) - No concurrent chemotherapy Endocrine therapy - More than 4 weeks since prior anticancer hormonal therapy except gonadotropin-releasing hormone agonists - Concurrent androgen suppression for the treatment of prostate cancer allowed Radiotherapy - More than 4 weeks since prior anticancer radiotherapy Surgery - Not specified Other - Recovered from prior therapy - No prior topotecan - At least 2 weeks since prior and no other concurrent investigational agents administered as part of a phase 0 study - No concurrent herbal or alternative medications except a single daily multivitamin



Primary Contact:

Study Chair
Giovanni Melillo, MD
National Cancer Institute - Frederick

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.